🇺🇸 Medical Council Step exam for International Medical Graduates / ECFMG Certification · subject

Medical Council Step exam for International Medical Graduates / ECFMG Certification USMLE Step 3: Advanced Clinical Management & Computer-Based Case Simulations Syllabus

The USMLE Step 3: Advanced Clinical Management & Computer-Based Case Simulations syllabus for Medical Council Step exam for International Medical Graduates / ECFMG Certification in full: 4 chapters, 16 topics and 3 sub-topics, every one listed below, plus 50 USMLE Step 3: Advanced Clinical Management & Computer-Based Case Simulations flashcards with answers.

4Chapters
16Topics
3Sub-topics
50Flashcards

USMLE Step 3: Advanced Clinical Management & Computer-Based Case Simulations syllabus: all 4 chapters

Expand any chapter to see its topics and sub-topics.

  1. Foundations of Independent Practice (FIP)

    4 topics
    • Biostatistics and epidemiology applied to practice
    • Interpretation of medical literature and pharmacology
    • Patient safety and quality in the practice setting
    • Social and systems-based foundations of care
  2. Advanced Clinical Medicine (ACM) Across Settings

    4 topics
    • Management in ambulatory/office settings
    • Management in emergency department settings
    • Management in inpatient and ICU settings
    • Initial vs continued care decision points
  3. Computer-Based Case Simulations (CCS)

    4 topics
    • CCS Software & Workflow
      • Ordering tests, treatments, and monitoring
      • Advancing simulated clock and location changes
      • Re-evaluating and adjusting management
    • Acute and emergent case management strategies
    • Chronic disease longitudinal management
    • Avoiding harmful or unnecessary interventions
  4. Health Maintenance & Population Health

    4 topics
    • Age-appropriate preventive care and screening
    • Immunization across the lifespan
    • Risk factor modification and counseling
    • Disease surveillance and public health reporting

Medical Council Step exam for International Medical Graduates / ECFMG Certification USMLE Step 3: Advanced Clinical Management & Computer-Based Case Simulations flashcards — 50 questions with answers

  1. How is the sensitivity of a diagnostic test calculated, and what is it best used for clinically?

    Sensitivity = TP / (TP + FN) — the proportion of truly diseased people who test positive. Highly sensitive tests are best for ruling OUT disease when negative (SnNout).

  2. How is specificity calculated, and what is its clinical rule of thumb?

    Specificity = TN / (TN + FP) — the proportion of truly healthy people who test negative. Highly specific tests are best for ruling IN disease when positive (SpPin).

  3. Define positive predictive value (PPV) and state how disease prevalence affects it.

    PPV = TP / (TP + FP) — probability that a person with a positive test truly has disease. PPV rises as prevalence increases and falls as prevalence decreases.

  4. Define negative predictive value (NPV) and its relationship to prevalence.

    NPV = TN / (TN + FN) — probability that a person with a negative test is truly disease-free. NPV rises as prevalence falls (lower pretest probability).

  5. What are the formulas for the positive and negative likelihood ratios?

    LR+ = sensitivity / (1 − specificity); LR− = (1 − sensitivity) / specificity. LR+ >10 and LR− <0.1 produce large, often conclusive changes in disease probability.

  6. Distinguish relative risk (RR) from the odds ratio (OR), and state which study designs use each.

    RR = risk in exposed / risk in unexposed (used in cohort/RCT). OR = odds of exposure in cases / odds in controls (used in case-control). OR approximates RR when disease is rare.

  7. How are absolute risk reduction (ARR) and number needed to treat (NNT) calculated?

    ARR = control event rate − treatment event rate. NNT = 1 / ARR. NNT is the number of patients treated to prevent one additional bad outcome.

  8. What is the difference between incidence and prevalence?

    Incidence = NEW cases over a time period among those at risk (measures risk/rate). Prevalence = ALL existing cases at a point in time (incidence × average duration).

  9. Define a Type I and a Type II error in hypothesis testing.

    Type I (alpha) error = rejecting a true null hypothesis (false positive). Type II (beta) error = failing to reject a false null hypothesis (false negative).

  10. What is statistical power, how is it calculated, and what increases it?

    Power = 1 − beta = probability of detecting a true effect. It increases with larger sample size, larger effect size, lower variability, and a higher alpha.

  11. How is a 95% confidence interval interpreted for an odds ratio or relative risk?

    If the 95% CI for an OR/RR crosses 1.0, the result is not statistically significant. For a difference in means, crossing 0 indicates non-significance.

  12. What is lead-time bias versus length-time bias in screening studies?

    Lead-time bias = apparent survival gain only because disease is detected earlier, not because death is delayed. Length-time bias = screening preferentially detects slow, indolent disease with better prognosis.

  13. What is confounding, and name three ways to control for it.

    A confounder is independently associated with both exposure and outcome and is not on the causal pathway. Control via randomization, restriction, matching, stratification, or multivariable regression.

  14. Which statistical test compares means between two independent groups versus three or more groups?

    Two groups: Student's t-test. Three or more groups: ANOVA. Categorical/proportional data: chi-square test.

  15. What does intention-to-treat (ITT) analysis preserve in a randomized trial?

    ITT analyzes participants in their originally assigned groups regardless of adherence or dropout, preserving randomization and giving a real-world (more conservative) estimate of effect.

  16. Rank the strength of evidence among RCT, cohort, case-control, and case series.

    From strongest to weakest: systematic review/meta-analysis of RCTs > single RCT > cohort study > case-control study > case series/case report (expert opinion is lowest).

  17. What is a hazard ratio, and which analysis produces it?

    A hazard ratio compares the instantaneous event rate between two groups over time; it is derived from time-to-event (survival) analysis, typically Cox proportional hazards regression / Kaplan-Meier data.

  18. In pharmacology, define volume of distribution (Vd) and its formula.

    Vd = amount of drug in body / plasma drug concentration. A large Vd indicates extensive tissue distribution (lipophilic/protein-bound peripherally); it determines the loading dose.

  19. What is drug clearance and how does it relate to maintenance dosing?

    Clearance = rate of drug elimination / plasma concentration (volume cleared per unit time). Maintenance dose rate = clearance × target steady-state concentration.

  20. How is a drug's half-life calculated, and how many half-lives reach steady state?

    t½ = (0.693 × Vd) / clearance. Steady state and ~94–97% elimination are reached in approximately 4–5 half-lives.

Show the other 30 USMLE Step 3: Advanced Clinical Management & Computer-Based Case Simulations flashcards
  1. Differentiate zero-order from first-order elimination kinetics, giving a classic example of each.

    Zero-order: constant amount eliminated per time, independent of concentration (e.g., ethanol, phenytoin at high doses, aspirin overdose). First-order: constant FRACTION eliminated per time (most drugs).

  2. Define therapeutic index and explain why a narrow one matters.

    Therapeutic index = TD50 / ED50 (or LD50/ED50). A narrow therapeutic index (e.g., warfarin, digoxin, lithium, phenytoin) means small dose changes risk toxicity, requiring monitoring.

  3. Distinguish a competitive from a non-competitive antagonist on a dose-response curve.

    Competitive antagonist: shifts the agonist curve right, decreasing potency but Vmax/Emax is unchanged (surmountable). Non-competitive antagonist: lowers Emax/Vmax (insurmountable).

  4. What is the difference between drug efficacy and potency?

    Efficacy = maximal effect a drug can produce (Emax). Potency = amount of drug needed to produce a given effect (EC50); a more potent drug works at a lower dose but may have equal efficacy.

  5. Per the IOM/Reason 'Swiss cheese' model, what is the difference between an active error and a latent error?

    Active error: failure at the point of care (sharp end) with immediate effect (e.g., wrong dose given). Latent error: hidden system/design flaw (blunt end) that predisposes to failure (e.g., look-alike packaging).

  6. Define the patient-safety terms 'near miss' and 'sentinel event.'

    Near miss: an error that was caught before reaching the patient or caused no harm. Sentinel event: an unexpected occurrence causing death or serious physical/psychological injury, requiring immediate investigation (root cause analysis).

  7. What is the difference between root cause analysis (RCA) and failure mode and effects analysis (FMEA)?

    RCA is a retrospective, reactive investigation after an adverse event to find underlying causes. FMEA is a prospective, proactive analysis to identify and prevent potential failures before they occur.

  8. List the classic 'five rights' of medication administration.

    Right patient, right drug, right dose, right route, and right time. (Often expanded to include right documentation, reason, and response.)

  9. What is the purpose of a surgical 'time-out' and the universal protocol?

    A time-out is a final verification immediately before incision confirming correct patient, correct procedure, and correct site (site marking) to prevent wrong-site/wrong-patient/wrong-procedure surgery.

  10. Define the just culture approach to medical error.

    Just culture balances accountability with system learning—distinguishing blameless human error and at-risk behavior (coaching/system fixes) from reckless behavior (disciplinary action), encouraging error reporting.

  11. What are the six IOM/STEEEP aims for quality healthcare?

    Safe, Timely, Effective, Efficient, Equitable, and Patient-centered care (STEEEP).

  12. Differentiate the social determinants of health from health disparities.

    Social determinants of health are conditions in which people live and work (housing, income, education, food, environment) that shape outcomes. Health disparities are preventable differences in health burden between population groups.

  13. Under EMTALA, what are a hospital emergency department's legal obligations?

    EMTALA requires any Medicare-participating ED to provide a medical screening exam and stabilizing treatment to anyone, regardless of ability to pay or insurance, before transfer/discharge.

  14. Distinguish Medicare from Medicaid in the U.S. healthcare system.

    Medicare is federal insurance primarily for people aged 65+ and certain disabled persons/ESRD. Medicaid is a joint federal-state program covering low-income individuals; eligibility varies by state.

  15. What is the difference between primary, secondary, and tertiary prevention?

    Primary: prevent disease before onset (vaccines, counseling). Secondary: detect/treat early/asymptomatic disease (screening). Tertiary: reduce complications/disability in established disease (rehab, management). Quaternary: avoid overmedicalization.

  16. In the USMLE Step 3 CCS, what does advancing the simulated clock do, and why is order timing important?

    Advancing the clock lets time pass so ordered tests/treatments produce results and the patient's condition evolves. Order timing is scored—urgent interventions must be entered before advancing time in unstable patients.

  17. In the CCS interface, how do you change the patient's location, and why does it matter?

    Use the 'Change Location' button to move the patient (e.g., office→ED→ICU→ward→home). Choosing the appropriate level of care is scored; unstable patients need ICU/ED, stable ones can go home or to office follow-up.

  18. On the CCS, how are orders entered and what feedback confirms an action?

    Orders are typed on the order sheet (free-text recognized by the system) and confirmed; the clerk/screen confirms whether the order is done immediately, scheduled, or unavailable. Both diagnostic and therapeutic orders count.

  19. What is the recommended general CCS strategy for an unstable patient on presentation?

    Address ABCs and immediate stabilization first (oxygen, IV access, monitor, pulse oximetry), order urgent therapy before advancing the clock, place in appropriate high-acuity setting, then pursue diagnostics.

  20. What initial 'bundle' of orders is appropriate for nearly every acutely ill CCS patient?

    IV access, continuous cardiac monitor, pulse oximetry, and supplemental oxygen as needed—plus vital signs—before focused diagnostics and treatment.

  21. For an adult in pulseless ventricular fibrillation/pulseless VT, what is the immediate ACLS priority?

    Immediate high-quality CPR and early defibrillation (unsynchronized shock); give epinephrine 1 mg IV every 3–5 minutes and consider amiodarone after the third shock.

  22. What is the time-target ('door-to-needle' and 'door-to-balloon') management for acute STEMI?

    Reperfusion: primary PCI within 90 minutes of first medical contact (door-to-balloon), or fibrinolytics within 30 minutes (door-to-needle) if PCI unavailable; plus aspirin, P2Y12 inhibitor, anticoagulation.

  23. What defines sepsis and the initial 'Hour-1 bundle' of management?

    Sepsis = life-threatening organ dysfunction from dysregulated host response to infection (qSOFA/SOFA). Hour-1 bundle: measure lactate, obtain blood cultures before antibiotics, give broad-spectrum antibiotics, start 30 mL/kg crystalloid for hypotension/lactate ≥4, and add vasopressors for refractory hypotension.

  24. Contrast longitudinal chronic disease management with acute care decision-making.

    Chronic management emphasizes periodic monitoring, medication titration to targets (e.g., HbA1c, BP), lifestyle counseling, screening for complications, and continuity over time; acute care emphasizes rapid stabilization and diagnosis of an immediate threat.

  25. What HbA1c and blood-pressure targets guide longitudinal type 2 diabetes management?

    Generally HbA1c <7% for most adults (individualized), and blood pressure <130/80 mmHg; statin therapy and annual screening for retinopathy, nephropathy (urine albumin), and foot disease are standard.

  26. Give two examples of 'avoiding harmful or unnecessary interventions' from Choosing Wisely.

    Do not order routine imaging for acute low back pain without red flags, and do not prescribe antibiotics for viral upper respiratory infections—both reduce harm, cost, and antimicrobial resistance.

  27. What are the current adult colorectal cancer screening recommendations (USPSTF)?

    Screen average-risk adults beginning at age 45 through 75 (colonoscopy every 10 years, FIT annually, or other approved modalities); screening 76–85 is individualized.

  28. State the USPSTF recommendation for lung cancer screening.

    Annual low-dose CT for adults aged 50–80 with a 20 pack-year smoking history who currently smoke or quit within the past 15 years; stop after 15 years of cessation or if life expectancy is limited.

  29. What live vaccines are contraindicated in pregnancy and significant immunocompromise?

    Live vaccines such as MMR, varicella, live attenuated influenza (LAIV), and yellow fever are contraindicated in pregnancy and severe immunocompromise; give inactivated vaccines (e.g., Tdap, inactivated influenza) instead.

  30. Which infectious diseases are nationally notifiable and require public health reporting?

    Reportable conditions include tuberculosis, syphilis, gonorrhea, HIV/AIDS, measles, pertussis, hepatitis A/B/C, meningococcal disease, and many others—reported to local/state health departments and forwarded to the CDC for surveillance.

Medical Council Step exam for International Medical Graduates / ECFMG Certification USMLE Step 3: Advanced Clinical Management & Computer-Based Case Simulations FAQ

What is in the Medical Council Step exam for International Medical Graduates / ECFMG Certification USMLE Step 3: Advanced Clinical Management & Computer-Based Case Simulations syllabus?

Medical Council Step exam for International Medical Graduates / ECFMG Certification USMLE Step 3: Advanced Clinical Management & Computer-Based Case Simulations is split into 4 chapters: Foundations of Independent Practice (FIP), Advanced Clinical Medicine (ACM) Across Settings, Computer-Based Case Simulations (CCS) and Health Maintenance & Population Health. Together they contain 16 topics and 3 sub-topics.

How many chapters are in Medical Council Step exam for International Medical Graduates / ECFMG Certification USMLE Step 3: Advanced Clinical Management & Computer-Based Case Simulations?

4 chapters, containing 16 topics and 3 sub-topics. The largest chapter is Foundations of Independent Practice (FIP), with 4 topics.

Are there flashcards for Medical Council Step exam for International Medical Graduates / ECFMG Certification USMLE Step 3: Advanced Clinical Management & Computer-Based Case Simulations?

Yes — a 50-card USMLE Step 3: Advanced Clinical Management & Computer-Based Case Simulations deck, printed in full in the flashcards section of this page and available in the Examius app with spaced repetition. The free plan covers one exam of your choice, including its flashcards; Examius Pro, a one-time purchase, unlocks every other exam and deck.